Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib

Inhibition of KIT-signaling is a major molecular target for gastrointestinal stromal tumor (GIST) therapy, and imatinib mesylate (IM) is known as the most effective first-line treatment option for patients with advanced, unresectable, and/or metastatic GISTs. We show here for the first time that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Boichuk, Sergei, Galembikova, Aigul, Mikheeva, Ekaterina, Bikinieva, Firuza, Aukhadieva, Aida, Dunaev, Pavel, Khalikov, Dinar, Petrov, Semen, Kurtasanov, Refat, Valeeva, Elena, Kireev, Igor, Dugina, Vera, Lushnikova, Anna, Novikova, Maria, Kopnin, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352302/
https://www.ncbi.nlm.nih.gov/pubmed/32599808
http://dx.doi.org/10.3390/cancers12061674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352302/
https://www.ncbi.nlm.nih.gov/pubmed/32599808
http://dx.doi.org/10.3390/cancers12061674

Ejemplares similares